Novartis’ Mayzent and EMD Serono’s Mavenclad Look to Dethrone Genentech’s Ocrevus in the Expanding Patient Segment of Active Secondary Progressive Multiple Sclerosis
Following the recent relapsing forms of MS indication revision by the FDA, the unmet need for not active SPMS therapy has been put into stark contrast to other subtypes, while skepticism remains regarding the potential for MedDay Pharmaceuticals’ Qizenday, AB Science’s masitinib, or MediciNova’s ibudilast to emerge as the first-to-market solution, according to Spherix Global […]
Nephrologists Report Strong Willingness to Prescribe Off-Label Agents for Various Glomerular Diseases, According to Recent Market Intelligence from Spherix Global Insights
Conditions such as diabetic nephropathy, IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and lupus nephritis are associated with high unmet need EXTON, Pa., November 13, 2019/ PRNewswire/ — Throughout 2019, Spherix Global Insights has been collaborating with US nephrologists to identify areas of high unmet need and to detect late-stage clinical candidates with the most promise. […]
Janssen’s Darzalex Continues to Impress in Multiple Myeloma and New Indications Are Expected to Fuel Additional Growth
According to a recent survey conducted by Spherix Global Insights with 150 hematology-oncology specialists, the majority anticipate increasing their use of Darzalex as a result of the recent first-line approval of Darzalex/lenalidomide/dexamethasone (DRd) in transplant ineligible patients with multiple myeloma, and the group is largely optimistic about the potential approval of a subcutaneous formulation of […]
Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports
From: Multiple Sclerosis News Today By: Ana Pena, PHD Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports Prescriptions of two multiple sclerosis (MS) treatments — Merck KGaA‘s Mavenclad (cladribine) and Roche‘s Ocrevus (ocrelizumab) — have been rising in Europe over the past six months, bolstered by greater market […]
Positive Growth of Eli Lilly’s Taltz and Stabilization of Novartis’ Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift
Cosentyx’s first-to-market status in psoriasis, psoriatic arthritis, and ankylosing spondylitis has historically provided the brand with a competitive edge over in-class rival, Taltz, though recent studies conducted by Spherix Global Insights indicate changes are afoot EXTON, Pa., October 10, 2019 /PRNewswire/ — Novartis’ Cosentyx was first approved by the FDA for the treatment of psoriasis in […]
Benefitting From Expanded Access in Europe, Roche’s Ocrevus is on Track to Displace Biogen’s Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months
Italian and Spanish neurologists’ recent embrace of Merck KGaA’s Mavenclad, combined with a shift from Sanofi’s Lemtrada in the UK to Mavenclad, has helped boost share of the high-efficacy oral therapy, according to the 5th wave of the twice-yearly Spherix Global Insights report EXTON, Pa., October 7, 2019 ― Expanded access to Merck KGaA’s Mavenclad […]
Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly’s Third-to-Market Emgality to Second Place in the Anti-CGRP Class ― Surpassing Teva’s Ajovy
Allergan’s Botox appears indifferent to the chatter surrounding the anti-CGRP class launch, benefitting from high patient awareness and switch business opportunities following anti-CGRP discontinuations, according to the fifth wave of the quarterly Spherix Global Insights series EXTON, Pa., September 26, 2019 ― Nine months post launch, specialists’ self-reported share for Eli Lilly’s Emgality has surpassed […]
US Nephrologists Beginning to Trial AstraZeneca’s LOKELMA (zirconium sodium cyclosilicate) but Unclear on Differentiation from Vifor/Relypsa’s VELTASSA (patiromer FOS)
According to Spherix Global Insights, nephrologists surveyed in August report increased promotion and associated familiarity with Lokelma but express concerns about potential effects of sodium content. EXTON, Pa., / September 17, 2019 / PRNewswire – After two Complete Response Letters resulting in lengthy approval delays, AstraZeneca was finally able to introduce Lokelma, its novel treatment […]
Novartis’ Cosentyx and Pfizer’s Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights
While the alternate mechanism of action agents are becoming increasingly popular in the second- or later-lines of therapy, they are also forfeiting a substantial amount of potential share EXTON, Pa., September 13, 2019 /PRNewswire/ — The fourth annual patient chart audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in PsA (US) service includes the feedback […]
New data provide insight into anti-CGRP use
From: The Pharma Letter New data provide insight into anti-CGRP use A survey from industry analyst Spherix Global Insights suggests that more people may be using anti-calcitonin…(read more)
